HK1035493A1 - Muscarinic antagonists in the treatment of presbyopia - Google Patents

Muscarinic antagonists in the treatment of presbyopia

Info

Publication number
HK1035493A1
HK1035493A1 HK01106162A HK01106162A HK1035493A1 HK 1035493 A1 HK1035493 A1 HK 1035493A1 HK 01106162 A HK01106162 A HK 01106162A HK 01106162 A HK01106162 A HK 01106162A HK 1035493 A1 HK1035493 A1 HK 1035493A1
Authority
HK
Hong Kong
Prior art keywords
presbyopia
treatment
muscarinic antagonists
cholinergic
restore
Prior art date
Application number
HK01106162A
Other languages
English (en)
Inventor
Arlene Gwon
Mussie Elizabeth Wolde
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of HK1035493A1 publication Critical patent/HK1035493A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK01106162A 1998-07-30 2001-08-31 Muscarinic antagonists in the treatment of presbyopia HK1035493A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/126,064 US6291466B1 (en) 1998-07-30 1998-07-30 Cholinergic agents in the treatment of presbyopia
PCT/US1999/016260 WO2000006135A2 (en) 1998-07-30 1999-07-22 Cholinergic agents in the treatment of presbyopia

Publications (1)

Publication Number Publication Date
HK1035493A1 true HK1035493A1 (en) 2001-11-30

Family

ID=22422802

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01106162A HK1035493A1 (en) 1998-07-30 2001-08-31 Muscarinic antagonists in the treatment of presbyopia

Country Status (13)

Country Link
US (2) US6291466B1 (de)
EP (1) EP1100480B1 (de)
JP (1) JP2002521429A (de)
KR (1) KR20010079593A (de)
CN (1) CN1157186C (de)
AT (1) ATE250412T1 (de)
AU (1) AU754588B2 (de)
BR (1) BR9912599A (de)
CA (1) CA2339093A1 (de)
DE (1) DE69911620T2 (de)
ES (1) ES2207963T3 (de)
HK (1) HK1035493A1 (de)
WO (1) WO2000006135A2 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8911496B2 (en) 2006-07-11 2014-12-16 Refocus Group, Inc. Scleral prosthesis for treating presbyopia and other eye disorders and related devices and methods
AU2007272963B2 (en) 2006-07-11 2013-05-23 Refocus Group, Inc. Scleral prosthesis for treating presbyopia and other eye disorders and related devices and methods
ES2329161T3 (es) * 2006-12-18 2009-11-23 Jorge Luis Benozzi Composiciones oftalmicas de estimulantes parasimpaticos y antiinflamatorios para su uso en el tratamiento de la presbicia.
GB0711151D0 (en) * 2007-06-11 2007-07-18 Sra Dev Ltd Switch for use with an ultrasonic surgical tool
GB0724558D0 (en) * 2007-12-15 2008-01-30 Sharma Anant Optical correction
US8299079B2 (en) * 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
WO2010135731A1 (en) * 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
EP2512492A1 (de) * 2009-12-14 2012-10-24 University of Massachusetts Verfahren zur hemmung von grauem star und altersweitsichtigkeit
US8889735B2 (en) * 2011-04-07 2014-11-18 Sucampo Ag Method for treating asthenopia
MY168643A (en) 2011-09-20 2018-11-27 Allergan Inc Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism
EA029070B1 (ru) 2013-03-14 2018-02-28 Дзе Юниверсити Оф Массачусетс Способ задержки развития катаракты и пресбиопии
US9320709B2 (en) 2013-08-28 2016-04-26 Presbyopia Therapies Llc Storage stable compositions and methods for the treatment of refractive errors of the eye
US11179327B2 (en) 2013-08-28 2021-11-23 Lenz Therapeutics, Inc. Compositions and methods for the treatment of presbyopia
US9968594B2 (en) 2013-08-28 2018-05-15 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US10064818B2 (en) 2013-08-28 2018-09-04 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia
US9844537B2 (en) 2013-08-28 2017-12-19 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US9833441B2 (en) 2013-08-28 2017-12-05 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US9089562B2 (en) * 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US9314427B2 (en) 2013-08-28 2016-04-19 Presbyopia Therapies Llc Compositions and methods for the improvement of distance vision and the treatment of refractive errors of the eye
US10307408B2 (en) 2013-08-28 2019-06-04 Presbyopia Therapies, LLC Contact lens compositions and methods for the treatment of presbyopia
US10617763B2 (en) 2013-08-28 2020-04-14 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia
US20170007637A1 (en) * 2014-02-11 2017-01-12 Orasis Pharmaceuticals Ltd. Pharmacological ophthalmic composition for use in the correction of presbyopia and its administration
MX2017016518A (es) 2015-06-18 2018-05-28 Presbyopia Therapies Llc Composiciones y metodos para la mejora de la vision a distancia y el tratamiento de errores de refraccion del ojo.
US10736863B2 (en) 2015-11-13 2020-08-11 University Of Massachusetts Methods of inhibiting cataracts and presbyopia
CH711969A2 (it) * 2015-12-29 2017-06-30 Pinelli Roberto Composizione per il trattamento della presbiopia.
BR112019002967A2 (pt) 2016-08-19 2019-05-14 Orasis Pharmaceuticals Ltd. composição farmacêutica oftálmica, métodos de corrigir presbiopia, de reduzir o tamanho de uma pupila, de induzir miose, de aumentar a profundidade de campo, de diminuir a grandeza de aberrações de ordem superior e de melhorar a acuidade visual não corrigida de perto e de longe, implante, e, kit.
WO2019097318A1 (en) * 2017-11-17 2019-05-23 Cellix Bio Private Limited Compositions and methods for the treatment of eye disorders
EP3681500B1 (de) * 2018-04-24 2022-03-23 Allergan, Inc. Verwendung von pilocarpinhydrochlorid zur behandlung von presbyopie
EP3860600A4 (de) * 2018-10-06 2022-07-20 Biotheravision, Inc Ophthalmische zubereitungen eines muscarinagonisten und verwendungsverfahren
CN110496215A (zh) * 2019-08-23 2019-11-26 中国人民解放军总医院 一种治疗老视的水性滴眼液及其制备方法
KR20230042077A (ko) * 2020-09-11 2023-03-27 인트라투스-네바다, 인크. 노안, 원시, 난시, 감소된 입체시, 및 감소된 대비 감도를 치료하기 위한 조성물 및 방법
MX2023004276A (es) * 2020-10-14 2023-05-02 Santen Pharmaceutical Co Ltd Composicion farmaceutica estable.
US11648247B1 (en) 2021-12-16 2023-05-16 Lenz Therapeutics, Inc. Compositions and methods for the treatment of presbyopia
US20230263727A1 (en) 2022-01-14 2023-08-24 Somerset Therapeutics, Llc Ophthalmologically suitable low pka buffer-containing pilocarpine compositions and related methods
US11969410B2 (en) 2022-02-09 2024-04-30 Somerset Therapeutics, Llc Low pH pilocarpine and brimonidine compound formulations and related methods
WO2023190653A1 (ja) * 2022-03-30 2023-10-05 参天製薬株式会社 医薬製剤の滅菌法と包装体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166317A (en) * 1988-10-31 1992-11-24 Houston Biotechnology Incorporated Neurotrophic factor
FR2638970A1 (fr) 1988-11-16 1990-05-18 Corbiere Jerome Nouvelles compositions pharmaceutiques agissant sur la presbytie et leur procede d'obtention
ATE203666T1 (de) 1989-06-21 2001-08-15 Univ Pennsylvania Verwendung eines muskarinantagonists zur herstellung eines medikaments für die behandlung und regulierung der augenentwicklung
US5122522A (en) * 1989-06-21 1992-06-16 The Trustees Of The University Of Pennsylvania Treatment and control of ocular development
AU4653993A (en) 1992-07-02 1994-01-31 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia

Also Published As

Publication number Publication date
AU754588B2 (en) 2002-11-21
WO2000006135A3 (en) 2000-03-23
AU5216099A (en) 2000-02-21
US6291466B1 (en) 2001-09-18
ATE250412T1 (de) 2003-10-15
WO2000006135A2 (en) 2000-02-10
US6410544B1 (en) 2002-06-25
CA2339093A1 (en) 2000-02-10
DE69911620T2 (de) 2004-07-29
CN1157186C (zh) 2004-07-14
ES2207963T3 (es) 2004-06-01
EP1100480B1 (de) 2003-09-24
JP2002521429A (ja) 2002-07-16
BR9912599A (pt) 2001-05-02
KR20010079593A (ko) 2001-08-22
EP1100480A2 (de) 2001-05-23
DE69911620D1 (de) 2003-10-30
CN1311670A (zh) 2001-09-05

Similar Documents

Publication Publication Date Title
HK1035493A1 (en) Muscarinic antagonists in the treatment of presbyopia
BR0007699A (pt) Métodos para restaurar e/ou melhorar a acomodação de pseudofaquia
NZ334063A (en) use of a combination of a histamine H1 receptor antagonist and a histamine H3 receptor antagonist to treat upper airway allergic responses
HK1040053A1 (en) Use of fused pyrrolocarbazoles for preventing/treating damage to sensory hair cells and cochlear neurons
LV12603A (en) Method of treating hyperproliferative vascular disease using rapamycin eventually in combination with mycophenolic acid
IL130295A0 (en) Scleral prosthesis for treatment of presbyopia and other eye disorders
EP1555025A3 (de) Verwendung von Dehydroepiandrosteron-Analoga für die Behandlung von Asthma
PL347912A1 (en) Treatment of addiction and addiction-related behavior
DE69738667D1 (de) Vorbeugung und behandlung von kolonadenom oder kolonmikroadenom mit 6-fluorursodeoxycholsäure
MY112973A (en) Methods for inhibiting vascular smooth muscle cell migration
IL146887A0 (en) Improved scleral prosthesis for treatment of presbyopia and other eye disorders
KR920702622A (ko) 안구 발육의 치료 및 조절
IL126159A0 (en) Methods of treating or preventing interstitial cystitis
PT1007093E (pt) Metodos para o tratamento de desordens atraves da utilizacao de interleucina-9 e seus antagonistas
ATE214278T1 (de) Verfahren und medikament zum vermindern des jet- lags
HK1015692A1 (en) Ctla-8 in combination with g-csf or with g-csf and il-6, and use of ctla-8, for treating infections
MY113406A (en) Methods of inhibiting physiological conditions associated with an excess of bradykinin
EP0797994A3 (de) Verwendung eines oder mehrerer 5-HT-2 Rezeptor-Antagonisten zur Herstellung eines Wirkstoffs für die Behandlung der Symptome von giftigen Bissen oder Stichen
Cuypers et al. Therapy of cluster headache with histamine H1 and H2 receptor antagonists
EP1007050A4 (de) Verfahren zur behandlung von drogenmissbrauch
ATE306269T1 (de) Behandlung der exzessiven aggressivität mit olanzapine
EP0349589A4 (de) Pharmakologisch aktive cholinerge zubereitungen und verfahren zur herstellung und deren verwendung zur behandlung von krankheiten.
EP1019066A4 (de) Verfahren und zusammensetzungen zur vorbeugung und behandlung von sodbrennen
MD1296G2 (ro) Metoda Nicolau de tratament al lichenului plan bucal

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20070722